Contrast-enhanced MRI lesions during treatment with interferonβ-1b predict increase in T1 black hole volume in patients with relapsing-remitting multiple sclerosis

Multiple Sclerosis

Volumn 11, Issue 2, 2005, Pages 146-148

  Morgen, Katrin ^a,b   Crawford, A L T ^a,c   Stone, R D ^a   Martin, R ^a   Richert, N D ^a   Frank, J A ^d   McFarland, H F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Black holes; Contrast enhancing lesions; IFN 1b; Relapsing remitting MS

Indexed keywords

INTERFERON BETA SERINE;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ADULT; BRAIN; FEMALE; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 15544379472     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1147oa     Document Type: Article

References (10)

1. Van Walderveen MA, Kamphorst W, Scheltens P, van Waesberghe JH, Ravid R, Valk J et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998; 50: 1282-88.
2. Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR et al. Accumulation of hypointense lesions ('black holes') on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996; 47: 1469-76.
3. Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000; 55: 185-92.
4. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded status scale (EDSS). Neurology 1983; 33 1444-52.
5. Stone LA, Frank JA, Albert PS, Bash CN, Calabresi PA, Maloni H et al. Characterization of MRI response to treatment with interferon beta-1b: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997; 49: 862-69.
6. Giugni E, Paolillo A, Tomassini V, Mainero C, Gasperini C, Russo P et al. An active scan at 12th month of therapy is associated with a worse clinical response to IFNbeta over the subsequent five years of treatment in RRMS. Program and abstracts of the 55th Annual Conference of American Academy of Neurology, 2003: S31.003 (abstract).
7. Rudick RA, Cutter G, Baier M, Dougherty D, Weinstock-Guttman B, Mass M et al. Gadolinium enhancing lesions as a surrogate marker of interferon response. Mult Scler 2002; 8: S21 (abstract).
8. Brex P, Molyneux PD, Smiddy P, Barkhof F, Filippi M, Yousry T et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001; 57: 2185-90.
9. Stürzebecher S, Wandinger KP, Rosenwald A, Sathyarmoorthy M, Tzou A, Mattar P et al. Expression profiling identifies responder and non-responder phenotypes to interferon-β in multiple sclerosis. Brain 2003; 126: 1419-29.
10. Li SYI, Regal J, Soher BJ, Mannon LJ, Grossman RI, Gonen O. Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003; 24: 68-74.